Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

65.77
Delayed Data
As of Mar 29
 -0.21 / -0.32%
Today’s Change
55.06
Today|||52-Week Range
68.12
+5.03%
Year-to-Date
Vertex Pharmaceuticals hails new cystic fibrosis drug
Mar 28 / FT.com - Paid Partner Content
Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
Mar 24 / Zacks.com - Paid Partner Content
Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug
Mar 28 / TheStreet.com - Paid Partner Content
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
Mar 16 / Zacks.com - Paid Partner Content
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe
Mar 28 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data
Mar 16 / Zacks.com - Paid Partner Content
Amgen's Humira Biosimilar Approved in Europe
Mar 27 / GuruFocus News - Paid Partner Content